DONE: Roche Buying Genentech

At least big pharma is a source of M&A fees. Following news that Merck is buying Schering Plough, Roche and Genentech have FINALLY ended an ongoing maiting dance, as the Swiss drugmaker will buy out Genentech for $47 billion. Genentech, formally a Roche subsidiary before being spun out, had resisted the sale for the longest time, but eventually given the market uncertainty and Roche’s tenacity, gave in.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at